Cargando…

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients

BACKGROUND: Rearranged during transfection (RET) rearrangement has been identified as one of the crucial oncogenic drivers in non-small cell lung cancer (NSCLC). Recently, two highly selective RET inhibitors have been approved by the US Food and Drug Administration and demonstrated remarkable respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Junnan, Li, Yan, Wei, Bing, Guo, Lei, Li, Weihua, Xia, Qingxin, Zhao, Chengzhi, Zheng, Jiawen, Zhao, Jiuzhou, Sun, Rui, Guo, Yongjun, Brcic, Luka, Hakozaki, Taiki, Ying, Jianming, Ma, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073740/ https://www.ncbi.nlm.nih.gov/pubmed/35529790 http://dx.doi.org/10.21037/tlcr-22-202

Ejemplares similares

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients
por: Zhang, Kai, et al.
Publicado: (2019)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients
por: Khonrak, Thitima, et al.
Publicado: (2023)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
por: Wei, Bing, et al.
Publicado: (2019)

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
por: Tian, Yingying, et al.
Publicado: (2018)

Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

RET EXPRESSION AND ITS CORRELATION WITH CLINICOPATHOLOGIC DATA IN PAPILLARY THYROID CARCINOMA
por: Punda, Ante, et al.
Publicado: (2018)

Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
por: Ren, Pengfei, et al.
Publicado: (2022)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis
por: Cyniak-Magierska, Anna, et al.
Publicado: (2011)

miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease
por: Li, Shuangshuang, et al.
Publicado: (2016)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
por: Li, Tao, et al.
Publicado: (2023)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

Low Frequency of Rearrangements of the ret and trk Proto‐oncogenes in Japanese Thyroid Papillary Carcinomas
por: Wajjwalku, Worawidh, et al.
Publicado: (1992)

1p/19q codeletion and RET rearrangements in small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2016)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments
por: Yan, Chi, et al.
Publicado: (2022)

DNA Breaks at Fragile Sites Generate Oncogenic RET/PTC Rearrangements in Human Thyroid Cells
por: Gandhi, Manoj, et al.
Publicado: (2010)

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
por: Gainor, Justin F., et al.
Publicado: (2020)

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas
por: Tiurin, Vladislav I., et al.
Publicado: (2023)

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
por: Zhang, Tongyi, et al.
Publicado: (2023)

RET/PTC and CK19 Expression in Papillary Thyroid Carcinoma and Its Clinicopathologic Correlation
por: Shin, Eunah, et al.
Publicado: (2005)

Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model
por: Cahill, Susanne, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_lg2phpu944ilgida49k7a2s2ht